Hypothesis

We hypothesize that in aging human skeletal muscle, the catalytic efficiency (Vmax/Km) of carnitine acetyltransferase (CAT) declines due to age‑dependent hyperacetylation of the enzyme, which reduces its affinity for acetyl‑CoA and carnitine, thereby making CAT a downstream bottleneck after CPT1. L‑carnitine supplementation raises substrate levels but does not reverse the post‑translational inhibition, explaining why fatty‑acid oxidation improves without parallel gains in insulin sensitivity. Restoring CAT activity via SIRT3‑mediated deacetylation (or a CAT‑specific activator) should normalize Vmax/Km and uncouple oxidation from insulin resistance.

Mechanistic Rationale

1. CAT as a CoA buffer – CAT converts acetyl‑CoA + carnitine ↔ acetylcarnitine + CoA, maintaining free CoA for β‑oxidation (2).
2. Age‑related lysine acetyltransferase activity rises while SIRT3 deacetylase falls in aged muscle (4), leading to hyperacetylation of mitochondrial proteins.
3. Precedent: Hyperacetylation reduces Vmax of acetyl‑CoA synthetase and ACAT2 (5). By analogy, CAT hyperacetylation would increase Km for acetyl‑CoA/carnitine and lower Vmax.
4. L‑carnitine supplementation boosts free carnitine pool (1) and can drive the reaction forward by mass action, but cannot correct an enzyme with impaired catalytic turnover.
5. Disconnect with insulin sensitivity: If CAT remains rate‑limiting, acetyl‑carnitine accumulates, inhibiting pyruvate dehydrogenase and promoting lipid‑induced insulin resistance, explaining why oxidation rises without improved glucose handling.

Predictions & Experimental Design

• Prediction 1: CAT Vmax/Km measured in permeabilized fibers from older adults (>65 y) will be significantly lower than in young controls (<30 y), independent of free carnitine concentration.
• Prediction 2: L‑carnitine supplementation (2 g/day for 12 weeks) will increase muscle free carnitine by ~20 % ([1]) but will not normalize CAT Vmax/Km unless combined with a SIRT3 activator (e.g., honokiol) or CAT‑specific allosteric activator.
• Prediction 3: Hyperacetylated CAT immunoprecipitated from aged muscle will show reduced activity that is restored by in‑vitro deacetylation with recombinant SIRT3.

Design: Obtain vastus lateralis biopsies from young (n=15) and old (n=15) participants before and after 12‑week L‑carnitine ± honokiol arms. Measure:

• Free and total carnitine (LC‑MS).
• CAT protein level (Western).
• CAT acetylation status (immunoprecipitation + anti‑acetyl‑lysine blot).
• Enzyme kinetics in mitochondria‑isolated fractions using varying acetyl‑CoA and carnitine concentrations to derive Km and Vmax (Michaelis‑Menten fit).
• Palmitate‑oxidation rates and insulin‑stimulated glucose uptake (ex‑vivo).

Statistical plan: Two‑way ANOVA (age × treatment) with post‑hoc tests; significance set at p<0.05.

Potential Implications

If confirmed, this hypothesis would shift focus from merely increasing carnitine availability to preserving or restoring CAT catalytic quality. It would suggest that combinatorial nutraceuticals (L‑carnitine + SIRT3 activators) are required to fully rescue mitochondrial fatty‑acid oxidation in healthy aging, and that CAT hyperacetylation could serve as a biomarker for predicting responsiveness to carnitine‑based therapies.